Crosslinked Polycation Carrier Particles for Low-Cytotoxic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polycations used for nucleic acid and protein delivery exhibit high cytotoxicity due to the dissociation of the complex after cellular uptake, leading to the release of potentially harmful materials.
Innovation Solution
Development of polycation carrier particles formed by polymerizing acrylate monomers with hydrophilic monomers, which are crosslinked to create a net positive charge and undergo charge shifting under physiological conditions, reducing cytotoxicity and enabling controlled release of the encapsulated material.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If polycations are used as carrier particles for nucleic acid and protein delivery, then the delivery efficiency and cellular uptake are improved, but the cytotoxicity increases due to dissociation of the complex after cellular uptake
Solution Approach 1:
The patent modifies the chemical structure of polycations by incorporating specific monomers (acrylate monomers with hydrophilic groups) that change the particle's properties after cellular uptake. The crosslinked polycation structure undergoes conformational changes and degradation into biocompatible monomers, transforming from a cytotoxic state to a biocompatible state while maintaining delivery functionality.
Solution Approach 2:
The patent employs a degradable polycation carrier that is designed to be temporarily present in the cell, perform its delivery function, and then degrade into harmless byproducts. The crosslinked structure is intended to be short-lived within the cellular environment, breaking down after delivering the payload to eliminate cytotoxicity.
2Object-affected harmful factors
If crosslinked polycation carrier particles are used to reduce cytotoxicity, then biocompatibility is improved, but the manufacturing complexity increases due to the polymerization process
Solution Approach 1:
The patent creates a composite polycation structure by combining multiple monomer components (acrylate monomers with specific hydrophilic groups and crosslinking agents) during polymerization. This composite approach achieves the desired biocompatibility and crosslinked structure through a single polymerization process, avoiding the need for separate modification steps.
Solution Approach 2:
The patent optimizes polymerization parameters (monomer ratios, crosslinking density, molecular weight) to achieve the desired balance between structural integrity for delivery and degradability for biocompatibility. By controlling these parameters during manufacturing, the complex crosslinked structure is produced efficiently without requiring overly complex processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polycation carrier particles achieve reduced cytotoxicity and improved biocompatibility by degrading into biocompatible small molecules, facilitating controlled intracellular release of therapeutic agents.
Implementation Method 1
the polycation carrier particle has charge shifting properties
Implementation Method 2
degrading into biocompatible small molecules
Data Source
AI summary
A polycation carrier particle obtained by the polymerization of a multiacrylate monomer with one or more hydrophilic monomers to form crosslinks. The polycation carrier particle has a net positive electric charge. The multiacrylate monomer and the hydrophilic monomer(s) are as defined herein.